What was the market valuation for hemiplegic migraine in 2024?

The market valuation for hemiplegic migraine was $134.0 Million in 2024. Read More

What is the projected market valuation for hemiplegic migraine by 2035?

The projected market valuation for hemiplegic migraine is $216.0 Million by 2035. Read More

What is the expected CAGR for the hemiplegic migraine market during the forecast period 2025 - 2035?

The expected CAGR for the hemiplegic migraine market during the forecast period 2025 - 2035 is 4.44%. Read More

What are the segment valuations for Familial and Sporadic Hemiplegic Migraine?

The segment valuation for Familial Hemiplegic Migraine is between $40.0 Million and $65.0 Million, while Sporadic Hemiplegic Migraine ranges from $94.0 Million to $151.0 Million. Read More

What are the treatment segment valuations for hemiplegic migraine?

The treatment segment valuations include Acute treatment at $30.0 Million to $50.0 Million, Triptans at $25.0 Million to $40.0 Million, and Ergotamines at $15.0 Million to $25.0 Million. Read More

What is the market valuation for hospitals and clinics as end-users?

The market valuation for hospitals and clinics as end-users is between $60.0 Million and $100.0 Million. Read More

What are the preventive treatment segment valuations for hemiplegic migraine?

Preventive treatment segment valuations include Antidepressants at $40.0 Million to $65.0 Million and Botox Injections at $50.0 Million to $80.0 Million. Read More

How do retail pharmacies compare to hospital pharmacies in terms of distribution channel valuation?

Retail pharmacies have a valuation between $40.0 Million and $64.0 Million, whereas hospital pharmacies range from $30.0 Million to $48.0 Million. Read More

What does the future hold for the hemiplegic migraine market in South America?

The hemiplegic migraine market in South America is expected to grow, reaching a valuation of $216.0 Million by 2035. Read More

South America Hemiplegic Migraine Market

Q: Which companies are key players in the hemiplegic migraine market?

Key players in the hemiplegic migraine market include Amgen Inc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Novartis AG, Pfizer Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company. Read More

ID: MRFR/HC/51967-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

South America Hemiplegic Migraine Market Research Report By Type (Familial, Sporadic), By Treatment (Acute, Preventive), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By End-user (Hospitals & Clinics, Diagnostic Centers, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035

South America Hemiplegic Migraine Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.44%

2024 Market Size$ 134 Million

2025 Market Size$ 139.95 Million

2035 Market Size$ 216 Million

Key Players

Amgen Inc

Teva Pharmaceutical Industries Ltd

Eli Lilly and Company

Novartis AG

Pfizer Inc

AstraZeneca PLC

Trends

Increased Awareness and Diagnosis
Demand for Personalized Treatment
Research and Development Initiatives

Opportunities

Increased Healthcare Expenditure
Advancements in Treatment Options
Rising Incidence of Hemiplegic Migraine

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
  1. 4.1.1 Familial Hemiplegic Migraine
  2. 4.1.2 Sporadic Hemiplegic Migraine
2. 4.2 Security, Access Control and Robotics, BY Treatment (USD Million)
  1. 4.2.1 Acute treatment
  2. 4.2.2 Triptans
  3. 4.2.3 Ergotamines
  4. 4.2.4 NSAIDs
  5. 4.2.5 Antiemetics
  6. 4.2.6 Narcotic Analgesics
  7. 4.2.7 Others
3. 4.3 Security, Access Control and Robotics, BY End-user (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Diagnostic Centers
  3. 4.3.3 Others
4. 4.4 Security, Access Control and Robotics, BY Preventive Treatment (USD Million)
  1. 4.4.1 Antidepressants
  2. 4.4.2 Botox Injections
  3. 4.4.3 Others
5. 4.5 Security, Access Control and Robotics, BY Distribution Channel (USD Million)
  1. 4.5.1 Retail Pharmacies
  2. 4.5.2 Hospital Pharmacies
  3. 4.5.3 Online Pharmacies
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca PLC (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Boehringer Ingelheim GmbH (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY END-USER
5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY PREVENTIVE TREATMENT
6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER, 2024 (% SHARE)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER, 2024 TO 2035 (USD Million)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PREVENTIVE TREATMENT, 2024 (% SHARE)
20. 6.20 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PREVENTIVE TREATMENT, 2024 TO 2035 (USD Million)
21. 6.21 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
  4. 7.2.4 BY PREVENTIVE TREATMENT, 2025-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South America South America Hemiplegic Migraine Market Segmentation

South America Hemiplegic Migraine Market By Type (USD Million, 2025-2035)

Familial Hemiplegic Migraine
Sporadic Hemiplegic Migraine

South America Hemiplegic Migraine Market By Treatment (USD Million, 2025-2035)

Acute treatment
Triptans
Ergotamines
NSAIDs
Antiemetics
Narcotic Analgesics
Others

South America Hemiplegic Migraine Market By End-user (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Others

South America Hemiplegic Migraine Market By Preventive Treatment (USD Million, 2025-2035)

Antidepressants
Botox Injections
Others

South America Hemiplegic Migraine Market By Distribution Channel (USD Million, 2025-2035)

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”